CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

Home About What We Do Programs and Services CADTH Reimbursement Review Adalimumab

Adalimumab

Last Updated: October 9, 2018

Result type: Reports

Project Number: SR0450-000

Product Line: Reimbursement Review

Generic Name: Adalimumab

Brand Name: Humira

Manufacturer: AbbVie Corporation

Therapeutic Area: Ulcerative colitis

Indications: Ulcerative Colitis

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: April 15, 2016

Recommendation Type: Do not list at the submitted price

Adalimumab

Files